title: Clinical trial with authentic recombinant somatropin in Japan.
abstract: Recombinant somatropin, produced by recombinant DNA technology, was administered by injection in daily doses of 8 IU to six healthy young volunteers. Daily injection for 4 days did not cause any significant change in the results of physical examination, blood count or urinalysis. Non-esterified fatty acid levels increased significantly from 0.45 +/- 0.16 to 1.08 +/- 0.12 mEq/litre (mean +/- SEM) at 4 hours after the first injection (p less than 0.001). Plasma IGF-1 levels increased from 0.80 +/- 0.14 units/ml to 1.72 +/- 0.50, 3.22 +/- 1.02, 3.17 +/- 1.20 and 3.63 +/- 0.78 units/ml at 24 hours after each daily injection for 4 days (p less than 0.001). Plasma hGH reached peak levels at 3 hours after intramuscular injection of recombinant somatropin, 4 IU, and this peak value was 57.3 +/- 2.8 ng/ml. A total of 21 patients with pituitary dwarfism were also treated with recombinant somatropin for 6 months at a dose of 0.5 IU/kg/week. Their heights increased by 2.2-5.0 cm during the 6 months of treatment, which was calculated to be equivalent to 4.4-10.0 cm/year with a mean growth rate of 7.4 +/- 0.4 cm/year. Anti-hGH antibody with a titre of 10 was observed in two patients at the end of 6 months of treatment.
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: K
authors.initials: K
authors.lastname: Shizume
authors.forename: I
authors.initials: I
authors.lastname: Hibi
authors.forename: A
authors.initials: A
authors.lastname: Okuno
authors.forename: H
authors.initials: H
authors.lastname: Nakajima
authors.forename: S
authors.initials: S
authors.lastname: Suwa
authors.forename: T
authors.initials: T
authors.lastname: Nogawa
authors.forename: T
authors.initials: T
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Momoi
authors.forename: N
authors.initials: N
authors.lastname: Iwatani
mesh_terms: D000293:Adolescent; D000328:Adult; D000365:Age Determination by Skeleton; D000906:Antibodies / Q000032:analysis; D001827:Body Height; D002648:Child; D002986:Clinical Trials as Topic; D004393:Dwarfism, Pituitary / Q000188:drug therapy; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000172:deficiency / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000097:blood; D007564:Japan; D007700:Kinetics; D008297:Male; D011994:Recombinant Proteins / Q000097:blood / Q000627:therapeutic use*
chemical_list: D000906:Antibodies; D005230:Fatty Acids, Nonesterified; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone